Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
New 6-in-1 vaccine schedule study in UK children
ISRCTN60488657Phase 4Active, not recruiting
- Sponsor
- University of Oxford
- Start
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Biotherapeutic Products → Microbiome Therapeutics
01
Overview
Phase 4, randomised, open-label trial of pertussis filamentous haemagglutinin, DTaP-IPV-Hep B-PRP-T vaccine, meningococcal group B vaccine, pneumococcal 13-valent conjugate vaccine, measles, mumps and rubella vaccine (live) and 2 more in Haemophilus influenzae type b disease (Hib), hepatitis B (HBV), diphtheria and 9 more (4 arms), sponsored by University of Oxford. Primary endpoint: Anti-PRP (Hib) IgG concentration at 19 months. Started Sep 2023; status: active, not recruiting.
02
Drugs
pertussis filamentous haemagglutininDTaP-IPV-Hep B-PRP-T vaccinemeningococcal group B vaccinepneumococcal 13-valent conjugate vaccinemeasles, mumps and rubella vaccine (live)
03
Conditions
Haemophilus influenzae type b disease (Hib)hepatitis B (HBV)diphtheriaTetanuspertussis
Beyond the preview
Go deeper on ISRCTN60488657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN60488657.